Business Context and Reporting Period
Company: SINTX Technologies, Inc. (SINTX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: SINTX is an advanced ceramics company specializing in silicon nitride (SiN) biomaterials for medical, industrial, and antipathogenic applications. The company operates a single reportable segment and manufactures products in Salt Lake City, Utah. Key products include spinal fusion implants, the recently FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System, and antipathogenic materials.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $1,018 | $2,887 |
| Gross Profit | $461 | $2,076 |
| Net Loss | $(10,364) | $(11,024) |
| Net Loss Attributable to Common Stockholders | $(17,083) | $(11,024) |
| Cash and Cash Equivalents (Dec 31, 2025) | $4,140 | $3,598 |
| Accumulated Deficit (Dec 31, 2025) | $(292,102) | $(281,738) |
| Net Cash Used in Operating Activities | $(8,571) | $(8,642) |
Liquidity: As of December 31, 2025, the company held $4.1 million in cash. It has an "At The Market" (ATM) offering program with $6.0 million of remaining capacity.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 65% to $1.0 million. Product revenue fell 41% and grant/contract revenue fell 82%. Management attributes this to a strategic shift away from low-margin OEM technical manufacturing contracts toward proprietary biomedical devices.
- Operating Expenses: Total operating expenses decreased 31% to $11.2 million. This was driven by the elimination of $4.6 million in "Armor exit costs" and $0.4 million in "Reduction in force" expenses incurred in 2024. However, General and Administrative (G&A) expenses increased 55% due to higher stock-based compensation and board fees.
- Net Loss: Net loss narrowed slightly by 6% to $10.4 million, primarily due to the reduction in one-time exit costs and a decrease in the change in fair value of derivative liabilities compared to 2024.
- Deemed Dividend: A $6.7 million deemed dividend related to a warrant inducement in September 2025 significantly increased the net loss attributable to common stockholders to $17.1 million.
Guidance, Outlook, and Risks
Strategic Outlook: Management is pivoting focus to high-growth biomedical sectors, specifically leveraging the October 2025 FDA 510(k) clearance for the SiNAPTIC® Foot & Ankle Osteotomy Wedge System. Commercial revenue from this product is expected to begin in the first half of 2026. The company also entered a private label agreement for OsseoSculpt™ biologic products.
Going Concern Warning: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern for 12 months from the issuance date. The company has a history of recurring losses and negative operating cash flows. Continued operations depend on raising additional financing, which is not guaranteed.
Key Risks:
- Capital Requirements: Failure to obtain additional funding could force delays in product development or commercialization.
- Market Acceptance: Limited market acceptance of silicon nitride products to date; success depends on surgeon adoption and reimbursement coverage.
- Regulatory: Dependence on FDA and international regulatory approvals for new product candidates.
- Intellectual Property: Lack of patent protection for the composition of matter for solid silicon nitride, leaving the company vulnerable to competitors developing similar formulations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.1 million cash balance against the $8.6 million annual operating cash burn rate.
- ATM Utilization: Monitor the execution of the $6.0 million remaining ATM offering capacity and potential dilution to existing shareholders.
- Commercialization Timeline: Confirm the start date of revenue recognition for the SiNAPTIC® Foot & Ankle system and OsseoSculpt™ products in 2026.
- Warrant Inducement Impact: Review the terms of the September 2025 warrant inducement and the associated $6.7 million deemed dividend impact on equity.
- Sublease Savings: Validate the expected $1.0 million savings from the sublease of the SINTX Armor facility.